• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TRxADE HEALTH Announces Launch of Preferred Drug Discount Card as Part of New Health Services Organization Offering

    11/30/21 8:35:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care
    Get the next $MEDS alert in real time by email

    TrxadeHSO™ Program Provides Healthcare-Adjacent Services to Vast User Network in Partnership with Paramount Rx, Empowering Independent Pharmacies to Remain at Forefront of Patient Care

    TAMPA, FL / ACCESSWIRE / November 30, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced the launch of its TRxADE Discount Card, empowering independent pharmacies to continue offering deeply discounted drug pricing to their customers while concurrently protecting margins and remaining at the forefront of patient care.

    Under its Health Services Organization (TrxadeHSO™) Program, Trxade aims to offer its network of 12,950+ members premier pharmacy and health-related services - all uniquely designed to empower pharmacies to provide better healthcare outcomes to consumers while growing their businesses as a local healthcare hub.

    Made possible through a strategic partnership with Paramount Rx, a full-service pharmacy benefits manager, TRxADE HEALTH's Preferred Drug Discount Card offers a heavily discounted option for patients for one low flat-fee to providers, known as the administrative fee. All independent pharmacies that are part of the TRxADE HEALTH network will be eligible to participate, further eliminating the affordable prescription drug pricing divide between independent and chain pharmacies. This innovative solution, along with Trxade's proprietary supply chain platform, helps to foster price transparency across the continuum of care by protecting independent pharmacies who often see reduced margins when discount cards are utilized.

    "We are pleased to announce our TRxADE Discount Card program, the T-Rx™ Savings Card, offering our network of independents access to competitive prescription savings for their customers while concurrently maintaining a reasonable transaction-level margin profile - a feature unique to our TrxadeHSO™ solution, unlike other well established discount card providers," said Prashant Patel, RPh, President of TRxADE HEALTH. "Other major prescription drug discount providers either exclude independents from the network or offer preferred rates to retail enterprise partners, resulting in higher fees for the independents and their patients when their benefit is utilized by the patient. Our model uniquely provides a win-win situation for all key stakeholders while further enhancing the value of the TRxADE platform to the independent pharmacy community.

    "Independent pharmacies aim to provide a patient-centric approach to care for their members, but far too often they face the overwhelming pressure of negative reimbursements and claw backs from pharmacy benefit managers in the form of direct and indirect renumeration (DIR) fees. Through this collaborative partnership - a key first step in our broader TRxADE HSO strategy - we are able to offer a true win-win solution to both patients and pharmacy providers. I look forward to announcing exciting new opportunities for our pharmacy partners in the months to come," concluded Patel.

    "Our independent pharmacies provide invaluable services to so many communities across the country. We are proud to partner with TRxADE and their family of pharmacies to better serve the millions of Americans in need of more affordable medications," added Michael Sallusto, Executive V.P. at Paramount Rx, Inc.

    About TRxADE HEALTH, INC.

    TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 12,950+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For info on TRxADE HEALTH, please visit the Company's IR website at investors.trxadegroup.com.

    About Paramount Rx Inc.

    Paramount Rx is a full-service prescription benefits manager (PBM) focused on consumer-driven health care to help clients provide services for consumers to save money on prescription drugs. The company has tailored programs to help their customers and consumers achieve significant savings with discount prescriptions through a national network of over 57,000 participating pharmacies. For more information, visit www.paramountrx.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to the adoption of our MedCheks app by partners and end-users, the apps of other competitors, including governments which may make certain apps mandatory or free, our ability to gain traction for our app in the marketplace, and the continued demand for our app; risks related to our operations not being profitable; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and possible recessions caused thereby; risks associated with the market for health passports, adoption thereof, consumer acceptance thereof, and changes in the market for such products; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

    Media Contact:
    TRxADE HEALTH, INC.
    [email protected]

    Investor Relations:
    Lucas Zimmerman
    Director
    MZ Group - MZ North America
    (949) 259-4987
    [email protected]
    www.mzgroup.us

    SOURCE: TRxADE HEALTH, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/675170/TRxADE-HEALTH-Announces-Launch-of-Preferred-Drug-Discount-Card-as-Part-of-New-Health-Services-Organization-Offering

    Get the next $MEDS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MEDS

    DatePrice TargetRatingAnalyst
    12/9/2021$4.50Buy
    EF Hutton
    More analyst ratings

    $MEDS
    SEC Filings

    View All

    TRxADE HEALTH Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    9/24/24 4:05:38 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    SEC Form DEF 14C filed by TRxADE HEALTH Inc.

    DEF 14C - TRxADE HEALTH, INC (0001382574) (Filer)

    8/28/24 4:05:30 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    SEC Form PRE 14C filed by TRxADE HEALTH Inc.

    PRE 14C - TRxADE HEALTH, INC (0001382574) (Filer)

    8/15/24 9:57:20 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $MEDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on Trxade Health with a new price target

    EF Hutton initiated coverage of Trxade Health with a rating of Buy and set a new price target of $4.50

    12/9/21 9:10:50 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    Maxim Group initiated coverage on Trxade Group

    Maxim Group initiated coverage of Trxade Group with a rating of Buy

    2/26/21 8:08:35 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $MEDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Shankar Hariharan claimed ownership of 97,087 shares (SEC Form 3)

    3 - TRxADE HEALTH, INC (0001382574) (Issuer)

    8/5/24 9:23:01 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    New insider Narasimhan Mani claimed ownership of 57,977 shares (SEC Form 3)

    3 - TRxADE HEALTH, INC (0001382574) (Issuer)

    8/5/24 9:23:00 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    Ajjarapu Surendra K was granted 10,000 shares (SEC Form 4) (Amendment)

    4/A - TRxADE HEALTH, INC (0001382574) (Issuer)

    5/28/24 5:01:21 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $MEDS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to "SCNX"

    TRxADE Health, Inc. today announced that it changed its name and ticker symbol to "Scienture Holdings, Inc." and "SCNX", respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the "Company") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX". Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions

    9/24/24 8:01:00 AM ET
    $MEDS
    $SCNX
    Other Pharmaceuticals
    Health Care

    TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

    TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. ("Scienture Holdings"), effective Monday, September 23, 2024. Scienture Holdings stock will begin trading under the new ticker symbol NASDAQ:SCNX on September 23, 2024. About TRxADE TRxADE HEALTH, INC. historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. Our current primary operations are conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC ("IPS"), whi

    9/20/24 11:59:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $MEDS
    Financials

    Live finance-specific insights

    View All

    TRxADE Health, Inc. Announces Special Cash Dividend

    TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, in

    7/9/24 8:05:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    TRxADE Health, Inc. Announces Special Cash Dividend

    TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, includi

    3/6/24 8:05:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

    Spero is another addition to the growing Superlatus CPG portfolio under their Urgent Company umbrella of brands.Spero® is a plant-based tech company specializing in alternative dairy and egg replacements, on a mission to outcompete traditional dairy and egg products in scale, price, taste, and nutrition by utilizing internationally patent-pending technologies that transforms low-cost, sustainable, and scalable ingredients into plant-based alternatives. Spero's mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere. TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. ("Superlatus"), wholly owned subsidary of

    10/4/23 8:05:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $MEDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by TRxADE HEALTH Inc. (Amendment)

    SC 13G/A - TRxADE HEALTH, INC (0001382574) (Subject)

    2/14/24 2:50:57 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by TRxADE HEALTH Inc.

    SC 13G - TRxADE HEALTH, INC (0001382574) (Subject)

    2/14/23 1:05:54 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by TRxADE HEALTH Inc. (Amendment)

    SC 13D/A - TRxADE HEALTH, INC (0001382574) (Subject)

    10/19/22 4:30:15 PM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    $MEDS
    Leadership Updates

    Live Leadership Updates

    View All

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

    TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader with over 25 years of experience in both the scientific and business areas of the pharmaceutical industry. He currently is a part of the Executives-in-Residence program at New Rhein Hea

    8/5/24 8:01:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care

    Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

    Forbes Fisher Appointed as Chief Operating Officer.Dr. Eugenio Bortone Appointed as Chief Innovation & Food Technology Officer. TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ:MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio (Gino) Bortone as Chief Innovation & Food Technology Officer. Forbes brings over 25 years of Food Services industry experience and will lead product innovation and information technology, and drive sales and supply chain optimization to support growth and profitability initiatives. Dr. Eugenio

    8/3/23 9:05:00 AM ET
    $MEDS
    Other Pharmaceuticals
    Health Care